NEUVASQ
NeuVasQ develops pharmaceuticals to restore blood-brain barrier function in neurological disorders such as alzheimer’s, and epilepsy.
NEUVASQ
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2021-01-01
Address:
Gosselies, Hainaut, Belgium
Country:
Belgium
Website Url:
http://www.neuvasq.com
Status:
Active
Email Addresses:
[email protected]
Total Funding:
20 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Nginx Organization Schema Typekit FLoC Opt-Out FLoC SEOmatic
Similar Organizations
Alchemab Therapeutics
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Lucy Therapeutics
Lucy Therapeutics is a biotech company providing effective treatments for neurological diseases start with the mitochondria.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Founder
Investors List
Newton Biocapital
Newton Biocapital investment in Series A - NeuVasQ
Official Site Inspections
http://www.neuvasq.com
- Host name: 188.208.36.123.static.hosted.by.combell-ops.net
- IP address: 188.208.36.123
- Location: Belgium
- Latitude: 50.8509
- Longitude: 4.3447
- Timezone: Europe/Brussels
More informations about "NeuVasQ"
Neuvasq
Neuvasq Biotechnologies is a privately held research company focusing on the discovery and development of pioneering therapies to safeguard or rebuild central nervous system (CNS) …See details»
About us - Neuvasq
Neuvasq Biotechnologies raised €20 million in a syndicated Series A financing round led by Newton Biocapital, with the participation of public and private investors SFPI, Wallonie Entreprendre (formerly SRIW), Theodorus, …See details»
NeuVasQ - Crunchbase Company Profile & Funding
NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as …See details»
Neuvasq Biotechnologies - LinkedIn
Neuvasq Biotechnologies is a privately held research company focusing on the discovery and development of pioneering therapies to safeguard or rebuild central nervous system (CNS) barriers and...See details»
Pipeline – Neuvasq
Neuvasq researches and develops novel therapeutics to safeguard or restore neurovascular function in the CNS, and to help patients with severe neurological conditions.See details»
Neuvasq Biotechnologies S.A. - BioWin
Apr 5, 2023 · NeuVasQ Biotechnologies, a spin-off from the Université Libre de Bruxelles (ULB), is developing pharmaceuticals to sustain or restore the neurovascular function, a novel …See details»
NeuVasQ | Pharmaceutical - The Pharmaletter
By targeting the pathways responsible for BBB integrity, NeuVasQ has been able to restore lost functionality to the neurovasculature. Currently in a preclinical discovery phase, the Belgian …See details»
NeuVasQ Biotechnologies - VentureRadar
Website: https://neuvasq.com/ NeuVasQ Biotechnologies is a spin-off founded in February 2021 to develop pharmaceuticals to restore blood-brain barrier function in acute neurological …See details»
NeuVasQ: An innovative approach to fight against neurovascular …
NeuVasQ was founded based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB) generated by the laboratory of Prof. Benoit …See details»
Series A - NeuVasQ - 2021-06-24 - Crunchbase Funding Round …
Jun 24, 2021 · Organization Name . NeuVasQ . Announced Date Jun 24, 2021; Funding Type Series A; Funding Stage Early Stage Venture; Money Raised . €20M. Lead Investors. Edit …See details»
News – Neuvasq
Neuvasq Biotechnologies, a ULB spin-off developing pharmaceuticals to restore blood-brain barrier function, announces the appointment…See details»
NeuVasQ Appoints Former UCB Ventures VP and Partner …
Sep 20, 2022 · Gosselies, Belgium, 15 September 2022 – NeuVasQ Biotechnologies, a ULB spin-off developing pharmaceuticals to restore blood-brain barrier function, announces the …See details»
Newton Biocapital invests in NeuVasQ: EUR 20 million Series A
Brussels, Belgium, 22 June 2021 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced its investment …See details»
NeuVasQ Biotechnologies bags €20m in Series A financing
Jun 22, 2021 · NeuVasQ Biotechnologies has raised €20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute …See details»
NeuVasQ Appoints Former UCB Ventures VP and Partner …
Sep 20, 2022 · NeuVasQ Biotechnologies, a ULB spin-off developing pharmaceuticals to restore blood-brain barrier function, announces the appointment of Emmanuel Lacroix, PhD, MBA, as …See details»
Science - Neuvasq
Neuvasq’s scientific research is based on the groundbreaking discovery that the endothelial Wnt/β-catenin signaling pathway plays a crucial role in regulating the formation of blood …See details»
NeuVasQ Biotechnologies – Startups.Bio
NeuVasQ is a spin-off company from the University of Brussels aiming to repair neurovascular function in a range of disorders by restoring the integrity of the blood-brain barrier. The blood …See details»
Neuvasq looking to blood-brain barrier to target neurological …
Jul 12, 2021 · LONDON – Neuvasq Biotechnologies has launched with a €20 million (US$23.7 million) series A to take forward a new approach to treating neurological disorders by reversing …See details»
NeuVasQ - EU-Startups
NeuVasQ is based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB). The BBB regulates the exchange between the vascular system and …See details»
Neuvasq Biotechnologies appoints World-Leading Experts to …
Oct 20, 2023 · Neuvasq Biotechnologies (Neuvasq), a research and development company focused on advancing therapies that safeguard or rebuild CNS barriers and restore …See details»